http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1173802-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24aca9ded2638ea793d05360dde7a4a0 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-91 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-91 |
| filingDate | 1967-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1969-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1173802-A |
| titleOfInvention | Quinazolinones |
| abstract | 1,173,802. Substituted quinazolinones; amides. SUMITOMO CHEMICAL CO. Ltd. 10 Nov., 1967 [15 Nov., 1966], No. 51368/67. Heading C2C. Novel quinazolinone derivatives of the general formula wherein R represents hydrogen or an alkyl group having at least 2 carbon atoms, R<SP>1</SP> represents an alkyl or haloalkyl group and each of R<SP>2</SP> and X represents a halogen atom, are prepared by reacting the compounds of the general formulµ wherein R, X, R<SP>1</SP> and R<SP>2</SP> have the above significance and Z represents a hydroxy or alkoxy group or a halogen atom. 2 - Formamido- and 2 - n - butyrylamido - 6- chloro - benzoic acids are prepared by reacting 2 - amino - 6 - chloro - benzoic acid with formic acid and n-butyryl chloride respectively. Pharmaceutical compositions having central nervous system depressive activities contain the above quinazolinone derivatives as the active ingredient. The compositions may be administered orally. |
| priorityDate | 1966-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 21.